FDA 483 - Grifols Diagnostic Solutions Inc. - February 27, 2019

During an inspection, Grifols Diagnostic Solutions Inc. in Emeryville, CA, was cited for three observations. These included issues with software configuration preventing access to original chromatograms, manufacturing of a working seed stock not adhering to the approved BLA, and validation acceptance criteria for column use time limits not reflecting current practices.